Fmoc-S-tert-butyl-L-cysteine
Need Assistance?
  • US & Canada:
    +
  • UK: +

Fmoc-S-tert-butyl-L-cysteine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Fmoc-Amino Acids
Catalog number
BAT-003837
CAS number
67436-13-9
Molecular Formula
C22H25NO4S
Molecular Weight
399.50
Fmoc-S-tert-butyl-L-cysteine
IUPAC Name
(2R)-3-tert-butylsulfanyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
Synonyms
Fmoc-L-Cys(tBu)-OH; Fmoc-(R)-2-amino-3-(S-tert-butyl)propanoic acid; (2R)-3-tert-butylsulfanyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
Appearance
White powder
Purity
≥ 99% (HPLC)
Density
1.237±0.06 g/cm3
Melting Point
133-147 °C
Boiling Point
603.4±55.0 °C
Storage
Store at 2-8 °C
InChI
InChI=1S/C22H25NO4S/c1-22(2,3)28-13-19(20(24)25)23-21(26)27-12-18-16-10-6-4-8-14(16)15-9-5-7-11-17(15)18/h4-11,18-19H,12-13H2,1-3H3,(H,23,26)(H,24,25)/t19-/m0/s1
InChI Key
IXAYZHCPEYTWHW-IBGZPJMESA-N
Canonical SMILES
CC(C)(C)SCC(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
1.Side-chain anchoring strategy for solid-phase synthesis of peptide acids with C-terminal cysteine.
Barany G1, Han Y, Hargittai B, Liu RQ, Varkey JT. Biopolymers. 2003;71(6):652-66.
Many naturally occurring peptide acids, e.g., somatostatins, conotoxins, and defensins, contain a cysteine residue at the C-terminus. Furthermore, installation of C-terminal cysteine onto epitopic peptide sequences as a preliminary to conjugating such structures to carrier proteins is a valuable tactic for antibody preparation. Anchoring of N(alpha)-Fmoc, S-protected C-terminal cysteine as an ester onto the support for solid-phase peptide synthesis is known to sometimes occur in low yields, has attendant risks of racemization, and may also result in conversion to a C-terminal 3-(1-piperidinyl)alanine residue as the peptide chain grows by Fmoc chemistry. These problems are documented for several current strategies, but can be circumvented by the title anchoring strategy, which features the following: (a). conversion of the eventual C-terminal cysteine residue, with Fmoc for N(alpha)-amino protection and tert-butyl for C(alpha)-carboxyl protection, to a corresponding S-xanthenyl ((2)XAL(4)) preformed handle derivative; and (b).
Online Inquiry
Verification code
Inquiry Basket